Breaks Categories: News

TuesdayAug 11, 2026 1:35 pm

BioMedNewsBreaks — AOM Capital Completes $5.1 Million Financing for Therapeutics Company Acquisition 

AOM Capital announced the completion of a $5.1 million financing for a therapeutics company in connection with its acquisition of a pharmaceutical drug asset. The private investment and specialty bridge lending firm structured the financing around the specific requirements of the transaction, providing the capital needed to support the acquisition. AOM Capital said the transaction expands its activity in private credit, acquisition financing and special situations, with the firm focused on providing flexible capital for acquisitions, bridge transactions, growth initiatives and other complex or time-sensitive opportunities. To view the full press release, visit https://ibn.fm/imbdB About AOM Capital AOM Capital is a private investment and specialty bridge…

Continue Reading

MondayAug 10, 2026 9:10 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible. Lucid-MS…

Continue Reading

MondayAug 10, 2026 9:00 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million

Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, up from $2 million in the year-ago period, driven by approximately $11 million in net sales of TONMYA. The fibromyalgia treatment recorded 12,592 total prescriptions during the quarter, up 100% sequentially, while new patient prescriptions increased 36% and refills rose 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare and Medicaid channels, with coverage expected to reach approximately 145 million lives when a managed Medicare agreement takes effect Jan. 1, 2027. Tonix also continued advancing its clinical pipeline, enrolling the first…

Continue Reading

FridayAug 07, 2026 9:20 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year increase in net income to $715,697 on revenue of $9.0 million, up 3% from the prior-year period. Gross profit rose to $6.3 million, operating cash flow more than doubled to $707,131 and total assets increased to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, while the company repurchased and retired more than 3.7 million common shares during the quarter without adding debt. The company said all key operating subsidiaries remained profitable as it continued expanding the licensing footprint of its compounding pharmacy…

Continue Reading

WednesdayAug 05, 2026 12:26 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Publishes Peer-Reviewed Capture-Seq Study 

VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA ("ctDNA"). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for…

Continue Reading

TuesdayAug 04, 2026 1:25 pm

BioMedNewsBreaks — SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics 

SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets. SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company's leadership team and board of directors to discuss opportunities to unlock shareholder value. To view the full press release, visit https://ibn.fm/VFyBI About SRX Global Inc. SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction…

Continue Reading

MondayAug 03, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference

Oncotelic Therapeutics (OTCQB: OTLC) announced that CEO and Chairman Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET, where investors will have the opportunity to participate in a live question-and-answer session. The company will highlight recent progress, including advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, expansion of European clinical sites, validation of its Deciparticle(TM) platform through peer-reviewed publications, scalable cGMP manufacturing capabilities and continued development of its AI-driven drug discovery, robotics and nanomedicine platforms. To view the full press release, visit https://ibn.fm/fGHUt About…

Continue Reading

ThursdayJul 30, 2026 12:58 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Closes CAD$5 Million Private Placement to Advance Oncology Programs

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of its previously announced non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, representing a notional subscription amount of approximately CAD$5 million. The financing included the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit consisting of one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted…

Continue Reading

ThursdayJul 30, 2026 11:54 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Highlights Growing Clinical Evidence Supporting Nu.Q NETs Test 

VolitionRx Limited (NYSE American: VNRX) highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis, while releasing an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. The company said multiple studies have shown its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity and provide strong prognostic value for outcomes including organ failure and mortality. Volition said most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. The company believes its low-cost nucleosome quantification technology…

Continue Reading

WednesdayJul 29, 2026 9:00 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047. The company said its BiTAC platform is designed to improve the selectivity and…

Continue Reading